Literature DB >> 18762267

Inhaled non-capsulated Bacillus anthracis in A/J mice: nasopharynx and alveolar space as dual portals of entry, delayed dissemination, and specific organ targeting.

Ian J Glomski1, Fabien Dumetz, Gregory Jouvion, Michel R Huerre, Michèle Mock, Pierre L Goossens.   

Abstract

Bacillus anthracis virulence is dependent on toxins and capsule. Encapsulation is associated with dissemination. We hypothesized that eliminating capsule would modify the portal of entry and the spread of bacteria. Using a bioluminescent model of inhalational anthrax, we demonstrated that aerosolized spores of a capsule-deficient strain administered at moderate doses initiated infection in the nasopharynx. Dissemination beyond the nasopharynx was delayed for at least 24h and then targeted the kidneys. Interestingly, high intranasal doses led to spore germination in the alveoli. We conclude that eliminating capsule while maintaining toxin production alters dissemination, but allows infection initiation in the lungs.

Entities:  

Mesh:

Year:  2008        PMID: 18762267     DOI: 10.1016/j.micinf.2008.07.042

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  19 in total

Review 1.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

2.  Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax.

Authors:  Fabien Dumetz; Grégory Jouvion; Huot Khun; Ian Justin Glomski; Jean-Philippe Corre; Clémence Rougeaux; Wei-Jen Tang; Michèle Mock; Michel Huerre; Pierre Louis Goossens
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

3.  cis-Acting elements that control expression of the master virulence regulatory gene atxA in Bacillus anthracis.

Authors:  Jennifer L Dale; Malik J Raynor; Prabhat Dwivedi; Theresa M Koehler
Journal:  J Bacteriol       Date:  2012-05-25       Impact factor: 3.490

4.  Stenotrophomonas maltophilia strains replicate and persist in the murine lung, but to significantly different degrees.

Authors:  Ruella Rouf; Sara M Karaba; Jenny Dao; Nicholas P Cianciotto
Journal:  Microbiology (Reading)       Date:  2011-05-05       Impact factor: 2.777

5.  Differential role of the interleukin-17 axis and neutrophils in resolution of inhalational anthrax.

Authors:  Kévin Garraud; Aurélie Cleret; Jacques Mathieu; Daniel Fiole; Yves Gauthier; Anne Quesnel-Hellmann; Jean-Nicolas Tournier
Journal:  Infect Immun       Date:  2011-10-24       Impact factor: 3.441

Review 6.  Updating perspectives on the initiation of Bacillus anthracis growth and dissemination through its host.

Authors:  Zachary P Weiner; Ian J Glomski
Journal:  Infect Immun       Date:  2012-02-21       Impact factor: 3.441

7.  Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli.

Authors:  Matthew A Crawford; Yinghua Zhu; Candace S Green; Marie D Burdick; Patrick Sanz; Farhang Alem; Alison D O'Brien; Borna Mehrad; Robert M Strieter; Molly A Hughes
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

8.  Bacillus anthracis has two independent bottlenecks that are dependent on the portal of entry in an intranasal model of inhalational infection.

Authors:  David E Lowe; Stephen M C Ernst; Christine Zito; Jason Ya; Ian J Glomski
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

9.  Characterization of Bacillus anthracis persistence in vivo.

Authors:  Sarah A Jenkins; Yi Xu
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

10.  Inhalational anthrax (Ames aerosol) in naïve and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremia.

Authors:  Bradford W Gutting; Tonya L Nichols; Stephen R Channel; Jeffery M Gearhart; George A Andrews; Alan E Berger; Ryan S Mackie; Brent J Watson; Sarah C Taft; Katie A Overheim; Robert L Sherwood
Journal:  Front Cell Infect Microbiol       Date:  2012-06-28       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.